Our SMDC technology and Companion Imaging Diagnostics have broad application for a number of diseases. Cancers that over-express folate receptors, such as ovarian, non-small cell lung cancer (NSCLC), breast, colorectal, renal cell, and gastric cancer, affect more than 1 million people in the U.S., Japan and Europe. Folate is required for cellular division, and rapidly dividing cancer cells over-express receptors for the vitamin. It may be possible to treat these patients more effectively with a drug attached to a folate ligand that can be delivered directly to the folate receptors on the cancer cells. Endocyte is developing other targeting ligands beyond folate that may benefit additional cancer patients.
Looking beyond cancer, we are also advancing research to develop products that can target diseases such as rheumatoid arthritis, osteoarthritis, atherosclerosis, viral infections, and others.